EUVIMEDEUVIMED entdecken
Crossref

Exam 1: Risk Stratification of a Novel Noninvasive Fibrosis Score in Metabolic Dysfunction-Associated Steatotic Liver Disease

Clinical Gastroenterology and Hepatology · 2026-10 · 24 (10) · e11-e12

DOI: 10.1016/j.cgh.2026.07.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-10.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Exam 1: Risk Stratification of a Novel Noninvasive Fibrosis Score in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clinical Gastroenterology and Hepatology, 24(10), e11-e12. https://doi.org/10.1016/j.cgh.2026.07.030

Vancouver

Exam 1: Risk Stratification of a Novel Noninvasive Fibrosis Score in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clinical Gastroenterology and Hepatology. 2026;24(10):e11-e12. doi:10.1016/j.cgh.2026.07.030

BibTeX
@article{euvimed2026,
  title = {Exam 1: Risk Stratification of a Novel Noninvasive Fibrosis Score in Metabolic Dysfunction-Associated Steatotic Liver Disease},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {10},
  pages = {e11--e12},
  doi = {10.1016/j.cgh.2026.07.030}
}
Kostenlos starten →